Chemotherapy for metastatic bladder cancer.
Over the past decade, a large amount of information has been acquired regarding the use of chemotherapy for metastatic bladder cancer. Combination regimens including M-VAC and CMV have been developed that generate high response rates; however, the impact of chemotherapy on survival has been modest. The available data would strongly suggest that therapy needs to be improved, and therefore current regimens should not be considered the standards of care as much as the standards of comparison for improved future treatments.
Kantoff
P W
PW
Department of Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.
Scher
H I
HI
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use; D010752:Phosphoramide Mustards / Q000627:therapeutic use; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D014747:Vinblastine / Q000627:therapeutic use
D010752:Phosphoramide Mustards; D014747:Vinblastine; D004317:Doxorubicin; D002945:Cisplatin; D008727:Methotrexate